Zenas BioPharma, Inc. ZBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 4.09% | 8.47% | |||
| Gross Profit | -2.44% | -8.47% | |||
| SG&A Expenses | -6.89% | 8.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.69% | 8.47% | |||
| Operating Income | -0.40% | -8.47% | |||
| Income Before Tax | -37.48% | 66.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -37.62% | 66.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.62% | 66.32% | |||
| EBIT | -0.40% | -8.47% | |||
| EBITDA | -0.40% | -8.47% | |||
| EPS Basic | -21.29% | 67.91% | |||
| Normalized Basic EPS | 11.48% | -4.75% | |||
| EPS Diluted | -21.29% | 67.91% | |||
| Normalized Diluted EPS | 11.48% | -4.75% | |||
| Average Basic Shares Outstanding | 13.46% | 4.95% | |||
| Average Diluted Shares Outstanding | 13.46% | 4.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||